153 related articles for article (PubMed ID: 36384226)
1. Impact of short-term pausing of oral corticosteroids on blood eosinophil count in patients with severe asthma.
Biener L; Milger K; Suhling H; Korn S; Pizarro C; Skowasch D
Pneumologie; 2023 Jun; 77(6):357-362. PubMed ID: 36384226
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Vultaggio A; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Cameli P; Canonica GW; Caruso C; Centanni S; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Menzella F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Benci M; Boarino S; Schroeder JW
Respir Res; 2023 May; 24(1):135. PubMed ID: 37210543
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO
Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
[TBL] [Abstract][Full Text] [Related]
4. Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry.
Graff S; Vanwynsberghe S; Brusselle G; Hanon S; Sohy C; Dupont LJ; Peche R; Michils A; Pilette C; Joos G; Louis RE; Schleich FN
Respir Res; 2020 Aug; 21(1):214. PubMed ID: 32787967
[TBL] [Abstract][Full Text] [Related]
5. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Menzella F; Bargagli E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Caruso C; Centanni S; D'Amato M; Del Giacco S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Simoni L; Ori A; Boarino S; Vitiello G; Altieri E; Canonica GW
Respir Res; 2022 Feb; 23(1):36. PubMed ID: 35183167
[TBL] [Abstract][Full Text] [Related]
6. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
7. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma.
Lugogo NL; Kreindler JL; Martin UJ; Cook B; Hirsch I; Trudo FJ
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):171-176. PubMed ID: 32334141
[TBL] [Abstract][Full Text] [Related]
8. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.
Korn S; Cook B; Simpson LJ; Llanos JP; Ambrose CS
Adv Ther; 2023 Jul; 40(7):2944-2964. PubMed ID: 37233876
[TBL] [Abstract][Full Text] [Related]
10. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients.
Watanabe H; Shirai T; Hirai K; Akamatsu T; Nakayasu H; Tamura K; Masuda T; Takahashi S; Tanaka Y; Kishimoto Y; Oishi K; Saigusa M; Yamamoto A; Morita S; Asada K
J Asthma; 2022 Sep; 59(9):1796-1804. PubMed ID: 34348060
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
12. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.
Heaney LG; Perez de Llano L; Al-Ahmad M; Backer V; Busby J; Canonica GW; Christoff GC; Cosio BG; FitzGerald JM; Heffler E; Iwanaga T; Jackson DJ; Menzies-Gow AN; Papadopoulos NG; Papaioannou AI; Pfeffer PE; Popov TA; Porsbjerg CM; Rhee CK; Sadatsafavi M; Tohda Y; Wang E; Wechsler ME; Alacqua M; Altraja A; Bjermer L; Björnsdóttir US; Bourdin A; Brusselle GG; Buhl R; Costello RW; Hew M; Koh MS; Lehmann S; Lehtimäki L; Peters M; Taillé C; Taube C; Tran TN; Zangrilli J; Bulathsinhala L; Carter VA; Chaudhry I; Eleangovan N; Hosseini N; Kerkhof M; Murray RB; Price CA; Price DB
Chest; 2021 Sep; 160(3):814-830. PubMed ID: 33887242
[TBL] [Abstract][Full Text] [Related]
13. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
Heaney LG; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker SM; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan DC; Mansur AH; Fowler SJ; Niven RM; Howarth PH; Lordan JL; Menzies-Gow A; Harrison TW; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID;
Lancet Respir Med; 2021 Jan; 9(1):57-68. PubMed ID: 32916135
[TBL] [Abstract][Full Text] [Related]
14. Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Tran TN
J Allergy Clin Immunol Pract; 2017; 5(4):1050-1060.e9. PubMed ID: 28215604
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China.
Li Y; Deng Z; Wen J; Ou C; Cen X; Liao Y; Zhang Q; Xie J
Ann Med; 2024 Dec; 56(1):2311843. PubMed ID: 38316016
[TBL] [Abstract][Full Text] [Related]
17. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
[TBL] [Abstract][Full Text] [Related]
18. Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis.
Prazma CM; Bel EH; Price RG; Bradford ES; Albers FC; Yancey SW
Respir Res; 2019 May; 20(1):83. PubMed ID: 31053134
[TBL] [Abstract][Full Text] [Related]
19. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
Menzies-Gow A; Hoyte FL; Price DB; Cohen D; Barker P; Kreindler J; Jison M; Brooks CL; Papeleu P; Katial R
Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
